Military policy dictates that flight personnel in Iraq receive primaquine chemoprophylaxis for Plasmodium vivax malaria on redeploying to a non-malarious area. Several days after beginning such a regimen, a 26-year-old African-American pilot develops anemia, hemoglobinemia, and hemoglobinuria. Special studies will likely reveal an abnormality in which of the following?
Primaquine is known to cause hemolytic anemia in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD is an enzyme important in protecting red blood cells from oxidative damage. When someone with G6PD deficiency takes primaquine, the drug induces oxidative stress, leading to the breakdown of red blood cells. This results in hemolytic anemia, which can present with symptoms like anemia, jaundice, and hemoglobinuria.
The question mentions the patient is African-American. G6PD deficiency is more common in people of African, Mediterranean, or Asian descent, so this is a clue pointing towards G6PD deficiency. The other options might include other enzymes or conditions, but the key here is the drug-induced hemolysis linked to a specific enzyme deficiency.
Now, the incorrect options might be other enzymes like pyruvate kinase or enzymes related to other metabolic pathways. For example, pyruvate kinase deficiency causes chronic hemolytic anemia, but it's not typically triggered by drugs like primaquine. Another possibility is a deficiency in methemoglobin reductase, but that would present with methemoglobinemia, not hemoglobinuria. Also, other conditions like thalassemia or sickle cell trait might be considered, but they don't usually present with acute hemolysis after drug exposure.
The clinical pearl here is to remember that G6PD deficiency is a common cause of drug-induced hemolytic anemia, especially with oxidant drugs like primaquine, sulfonamides, or certain antibiotics. The high-yield fact is to associate G6PD deficiency with acute hemolysis after exposure to these agents, particularly in individuals from high-prevalence populations.
So, putting it all together, the correct answer is G6PD deficiency. The other options don't fit the acute presentation and the drug trigger.
**Core Concept**
Primaquine induces hemolytic anemia in **G6PD-deficient** individuals by triggering oxidative stress in red blood cells. **G6PD (glucose-6-phosphate dehydrogenase)** is a critical enzyme in the pentose phosphate pathway, protecting erythrocytes from oxidative damage. Deficiency leads to acute hemolysis when exposed to oxidant agents like primaquine.
**Why the Correct Answer is Right**
Primaquine is an oxidant drug that generates reactive oxygen species (ROS). In G6PD-deficient red blood cells, the lack of NADPH production (via G6PD) impairs glutathione regeneration, leaving cells vulnerable to ROS-induced membrane damage and hemolysis. This presents with anemia, hemoglobinemia (free hemoglobin in plasma), and hemoglobinuria (hemoglobin in urine), as seen in this patient. African Americans have a higher prevalence of G6PD deficiency due to X-linked inheritance and evolutionary selection against malaria.
**Why Each Wrong Option is Incorrect**
**Option A:** *Pyruvate kinase deficiency* causes chronic hemolytic anemia but is not drug-induced or acute.
**Option B:** *Methemoglobin reductase deficiency* leads to